REMINDER: Our user survey closes TODAY, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.875
Bid: 9.50
Ask: 10.25
Change: 0.175 (1.80%)
Spread: 0.75 (7.895%)
Open: 9.875
High: 9.875
Low: 9.875
Prev. Close: 9.70
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

28 Dec 2023 17:36

RNS Number : 1181Y
Scancell Holdings Plc
28 December 2023

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B63D3314

Issuer Name

SCANCELL HOLDINGS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An event changing the breakdown of voting rights

3. Details of person subject to the notification obligation

Name

Vulpes Investment Management Pte Ltd

City of registered office (if applicable)

SG

Country of registered office (if applicable)

Singapore

4. Details of the shareholder

Name

City of registered office

Country of registered office

Vulpes Life Sciences Fund

Cayman Islands

Cayman Islands

5. Date on which the threshold was crossed or reached

28-Dec-2023

6. Date on which Issuer notified

28-Dec-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

12.920000

0.000000

12.920000

119910847

Position of previous notification (if applicable)

14.36

14.36

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00B63D3314

119910847

12.920000

Sub Total 8.A

119910847

12.920000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

12. Date of Completion

13. Place Of Completion

London, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLFLFFDFALTFIV
Date   Source Headline
29th Jun 20164:40 pmRNSSecond Price Monitoring Extn
29th Jun 20164:35 pmRNSPrice Monitoring Extension
17th Jun 20167:00 amRNSSCIB1 Drug Product Supply
2nd Jun 20167:00 amRNSDevelopment of ImmunoBody® Vaccine
18th May 20167:00 amRNSOpens US Headquarters in San Diego
19th Apr 20167:00 amRNSDirector/PDMR Shareholding
11th Apr 20164:11 pmRNSHolding(s) in Company
6th Apr 20167:00 amRNSHolding(s) in Company
4th Apr 201610:17 amRNSResult of the open offer
1st Apr 20167:00 amRNSResult of open offer
23rd Mar 20167:00 amRNSWorld Cancer Vaccine Congress
11th Mar 20167:00 amRNSStrategic collaboration with Karolinska Institutet
11th Mar 20167:00 amRNSPosting of Circular
9th Mar 20162:07 pmRNSPlacing and Open Offer Close
9th Mar 20167:00 amRNSProposed Placing and Open Offer
23rd Feb 20167:00 amRNSPresenting at the Biotech Capital Conference
27th Jan 20169:00 amRNSAmendment to Options
27th Jan 20167:00 amRNSHalf Yearly Report
11th Jan 20167:00 amRNSSCIB1 Early Immune Effect Observed by ImmunTraCkeR
7th Jan 20167:00 amRNSDirectorate Change
5th Jan 20167:00 amRNSKey Moditope paper published in Cancer Research
18th Dec 20157:00 amRNSUS Phase II combination study with SCIB1
20th Oct 20151:05 pmRNSResults of AGM
20th Oct 20157:00 amRNSAGM Business Update
14th Oct 20157:00 amRNSDirectorate Change
6th Oct 20157:00 amRNSSix scientific presentations at PIVAC Conference
18th Sep 20157:00 amRNSFinal Results for the year ended 30 April 2015
16th Sep 20157:00 amRNSImmunoBody presented at Cancer Vaccines Conference
27th Aug 20154:42 pmRNSNotice of AGM
30th Jul 20157:00 amRNSCollaboration with ImmunID
9th Jul 20157:00 amRNSPatient recruitment completed for SCIB1 trial
2nd Jun 20157:00 amRNSSCIB1 data update in resected melanoma patients
17th Apr 20159:00 amRNSPoster on Moditope to be presented at AACR
24th Mar 20154:40 pmRNSSecond Price Monitoring Extn
24th Mar 20154:35 pmRNSPrice Monitoring Extension
24th Mar 20157:00 amRNSSCIB2 synergy with checkpoint inhibitor blockade
12th Jan 20157:00 amRNSPositive SCIB1 Phase 1/2 clinical trial update
15th Dec 20145:22 pmRNSHolding(s) in Company
10th Dec 20147:00 amRNSHalf Yearly Report
22nd Oct 20143:07 pmRNSChange of Registered Office
14th Oct 20146:19 pmRNSResult of AGM
14th Oct 20147:00 amRNSAppointment of Nominated Adviser and Broker
14th Oct 20147:00 amRNSAGM research and development update
30th Sep 20147:00 amRNSPresent at the 14th Annual Biotech in Europe Forum
19th Sep 20149:57 amRNSNotice of AGM
12th Sep 20147:00 amRNSPresenting at Upcoming Scientific Conferences
4th Sep 20147:00 amRNSFinal Results
12th Aug 20147:00 amRNSSynergy of SCIB1 with checkpoint inhibitors
19th Jun 20147:00 amRNSDirector/PDMR Shareholding
6th Jun 20147:00 amRNSDNA ImmunoBody Patent Granted in United States

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.